BRASTER S.A., Polish innovative company using liquid crystal contact thermography technology for breast oncology, finalized the building of its demand book as part of its new issue of stocks (private subscription of the E-series stocks). The Supervisory Board of the Company has accepted the Management-recommended issue specifications: 500,000 stocks, PLN 13 per piece, i.e. PLN 6.5 million worth of securities.

BRASTER S.A. finalized the building of its book of private demand for its new issue of the E-series stocks on 16/04/2014, so it has met its issue targets. In the next step, the Management Board, authorized by the Supervisory Board’s resolution, will proceed with offering the stocks to qualified persons.

Our new issue of stocks attracted much interest from investors. This verifies again that BRASTER S.A. is an attractive and promising investing target. We will use the money for the purposes identified for the issue. Most of them are driven by the conclusions from the ThermaCRAC trial.

They include the following, among others:

• Continued development of the result interpretation algorithm and creation of supporting tools, such as a thermographic map or software for automated interpretation of results;

• R&D work to improve ergonomics of operation of the device (e.g., shorter thermographic test time);

• Preparing the Company and launching investments in the launch of the TESTER.

"We have made another important step towards the launch of our unique invention on international markets. We are satisfied as the Company has proved its credibility once again. We keep our promises regarding the pursuit of the planned growth milestones and schedule. This is why the worth of the Company is growing and this is the best recommendation for investors.” – commented Krzysztof Pawelczyk, BRASTER S.A.’s President.